GlassScriptPhysician profile
Crystal L Bennett
NPI 1770839953
$7,145.29
in general payments reported to CMS, 2019-2025
36 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,072 · 2022: $1,203 · 2023: $1,624 · 2024: $1,463 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,822 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,822.12 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,405.81 | 2021-2025 | |
| Alkermes, INC. | $669.96 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $524.08 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $428.81 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $386.60 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $353.13 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $328.46 | 2022-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $312.97 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $285.53 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $270.94 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $269.28 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $267.72 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $259.87 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $195.49 | 2021-2023 | Abilify Maintena, Rexulti |
| Novo Nordisk INC | $146.81 | 2021-2025 | Ozempic, Rybelsus |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $139.42 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $137.18 | 2024-2025 | Fanapt |
| Indivior INC. | $120.67 | 2022-2024 | Perseris |
| Idorsia Pharmaceuticals US INC | $99.22 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $88.47 | 2021-2025 | Mounjaro |
| Collegium Pharmaceutical, INC. | $59.26 | 2025 | Jornay Pm |
| Astellas Pharma US INC | $57.35 | 2025 | Veozah |
| Evofem Biosciences, INC. | $52.04 | 2022-2025 | Phexxi, Solosec, Phexx |
| Ironshore Pharmaceuticals INC. | $44.89 | 2022-2023 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.01 | 2022-2023 | Jardiance |
| Eisai INC. | $33.49 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $23.23 | 2023 | Livalo |
| Biohaven Pharmaceuticals, INC. | $21.45 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.23 | 2021 | |
| Tris Pharma INC | $19.55 | 2022 | |
| Ibsa Pharma INC. | $18.35 | 2024 | Tirosint, Licart, Flector |
| Allergan, INC. | $17.19 | 2021 | |
| Adlon Therapeutics L.P. | $15.66 | 2021 | |
| Exact Sciences Corporation | $14.98 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $2.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.